Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis

被引:49
作者
Beyeler, C
Armstrong, M
Bird, HA
Idle, JR
Daly, AK
机构
[1] UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
[2] UNIV LEEDS,CLIN PHARMACOL UNIT,LEEDS,W YORKSHIRE,ENGLAND
关键词
D O I
10.1136/ard.55.1.66
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives-To determine whether particular genotypes for the cytochrome P450 enzyme CYP2D6, a polymorphic enzyme, are associated with susceptibility to ankylosing spondylitis (AS) and rheumatoid arthritis (RE), or linked with any specific clinical or familial features of the two conditions. Methods-CYP2D6 genotypes were determined in 54 patients with AS, 53 patients with RA, and 662 healthy controls. Leucocyte DNA was analysed for the presence of mutations by restriction fragment length polymorphism analysis with the restriction enzyme Xbal and by two separate polymerase chain reaction assays. Results-On the basis of odds ratio (OR), individuals with two inactive CYP2D6 alleles were more susceptible to AS than controls (OR 2.71, 95% confidence interval (Cl) 1.04 to 7.08), with a stronger effect for the CYP2D6B allele (OR 4.11, 95% CI 1.54 to 11.0). No significant differences in the distribution of overall genotypes and allele frequencies were observed between RA and controls. No significant relationships were found between the skeletal, extraskeletal or familial features of AS or RA (iritis, psoriasis, inflammatory enteropathy and rheumatoid nodules, keratoconjunctivitis sicca, pleuritis, rheumatoid and antinuclear factors) and the overall genotype. Conclusions-Our findings suggest a modest association between homozygosity for inactive CYP2D6 alleles, particularly CYP2D6B alleles, and susceptibility to AS. However, our results fail to demonstrate a genetic link between CYP2D6 genotype and RA.
引用
收藏
页码:66 / 68
页数:3
相关论文
共 15 条
  • [1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [2] ALTERED DISTRIBUTION OF DEBRISOQUINE OXIDATION PHENOTYPES IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    BAER, AN
    MCALLISTER, CB
    WILKINSON, GR
    WOOSLEY, RL
    PINCUS, T
    [J]. ARTHRITIS AND RHEUMATISM, 1986, 29 (07): : 843 - 850
  • [3] BEYELER C, 1994, J RHEUMATOL, V21, P1034
  • [4] THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE
    CHOLERTON, S
    DALY, AK
    IDLE, JR
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) : 434 - 439
  • [5] GENETIC AND METABOLIC CRITERIA FOR THE ASSIGNMENT OF DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P4502D6) PHENOTYPES
    DALY, AK
    ARMSTRONG, M
    MONKMAN, SC
    IDLE, ME
    IDLE, JR
    [J]. PHARMACOGENETICS, 1991, 1 (01): : 33 - 41
  • [6] GENOTYPING FOR POLYMORPHISMS IN XENOBIOTIC METABOLISM AS A PREDICTOR OF DISEASE SUSCEPTIBILITY
    DALY, AK
    CHOLERTON, S
    ARMSTRONG, M
    IDLE, JR
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 : 55 - 61
  • [7] GARDNER MJ, 1989, STATISTICS CONFIDENC
  • [8] HUMAN CYTOCHROMES-P450 - PROBLEMS AND PROSPECTS
    GONZALEZ, FJ
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (09) : 346 - 352
  • [9] KHAN MA, 1992, RHEUM DIS CLIN N AM, V18, P837
  • [10] SCLERODERMA IS ASSOCIATED WITH DIFFERENCES IN INDIVIDUAL ROUTES OF DRUG-METABOLISM - A STUDY WITH DAPSONE, DEBRISOQUIN, AND MEPHENYTOIN
    MAY, DG
    BLACK, CM
    OLSEN, NJ
    CSUKA, ME
    TANNER, SB
    BELLINO, L
    PORTER, JA
    WILKINSON, GR
    BRANCH, RA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) : 286 - 295